Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Gilead Sciences Worthy of Your Portfolio?

2016 was not a very good year for biotech stocks to say the least. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) lost over 20%, as broader market indexes hit new highs. Investors sold off biotech stocks over concerns of drug-pricing fueled by attacks during the Presidential campaign. Hillary Clinton blasted several companies that over-inflated the prices of their drugs and promised to go after the industry and its practices.

After the election, biotech stocks didn’t manage to recoup their losses, as Donald Trump also said that he would do something about the issue of drug pricing. Just a few days ago, Trump boasted about developing a system spurring competition in the drug industry, claiming that “pricing for the American people will come way down”. Well, after seeing Trump and Republicans’ plan to replace the Affordable Care Act, it will be interesting to see what they will do about drug pricing. Following Trump’s latest tweet, a number of pharma stocks took a hit. Nevertheless, since the beginning of the year, biotech stocks have been gaining ground, with IBB having gained nearly 13%.

Gilead Sciences, Inc. (NASDAQ:GILD) was no exception, as its stock plunged by some 27% last year. It is down by another 8% year-to-date, as the company reported a drop in sales and profits for the fourth quarter and issued soft guidance for 2017. Even though its non-GAAP EPS of $2.70 and revenue of $7.32 billion topped the estimates by $0.09 and $150 million, respectively, the figures represented drops of 19% and 14% respectively over the year.

For its fiscal 2017, the company expects revenue between $22.5 billion and $24.5 billion and Hep C drug sales of between $7.50 billion and $9.00 billion. The company’s hep C drugs also showed a drop in sales in the fourth quarter, as well as other products. However, the company’s HIV franchise has exhibited robust growth and many analysts and investors suggested betting on Gilead particularly for its HIV drugs rather than its hep C pipeline.

There are many reasons why Gilead Sciences, Inc. (NASDAQ:GILD)’s HIV drugs should be the key factor to invest in the stock. These drugs are effective, allowing people to manage their condition throughout their lifetime. At the same time, people with HIV have to take the drugs throughout their entire life, which represents an advantage in comparison with HCV drugs that have to be taken only during a course. Gilead dominates the market in the HIV space and sales of HIV drugs amassed over 40% of Gilead’s sales last year.

Follow Gilead Sciences Inc (NASDAQ:GILD)
Trade (NASDAQ:GILD) Now!

On the following page, we will discuss the hedge fund sentiment towards Gilead and see what some top investors think about the company.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.